UWCCC Molecular Tumor Board Registry

Hematologic Neoplasms Clinical Trial

Official title:

UWCCC Precision Medicine Molecular Tumor Board Registry

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03023202
• Other study ID #: UW15068
• Secondary ID: 2015-1370P30CA01
• Status: Recruiting
• Start date: March 30, 2016
• Est. completion date: March 2027

Study information

• Verified date: May 2024
• Source: University of Wisconsin, Madison
• Contact: Cancer Connect
• Phone: 8006228922
• Email: clinicaltrials[@]cancer.wisc.edu
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

This study seeks to evaluate the clinical utility of the Precision Medicine Molecular Tumor Board, and to track patient outcomes.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 5000
• Est. completion date: March 2027
• Est. primary completion date: March 2027
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Clinically suspected or histologically confirmed solid or hematological malignancy

• Undergoing genetic testing of tumor

• Ability to understand written informed consent document

• Willingness to sign written informed consent document

Exclusion Criteria:

• Pediatric patients (age<18 years) will be excluded due to a lack of expertise on the molecular tumor committee

Related Conditions & MeSH terms

• Hematologic Neoplasms
• Neoplasms
• Solid Neoplasm

Intervention

Other:
• PMMTB (Precision Medicine Molecular Tumor Board)
PMMTB is a clinical intervention, NOT a research intervention. The research component of this study is to observe the outcomes of the PMMTB.

Locations

Country	Name	City	State
United States	University of Wisconsin Carbone Cancer Center	Madison	Wisconsin

Sponsors (2)

Lead Sponsor	Collaborator
University of Wisconsin, Madison	National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Frequency of acceptance of molecular tumor board recommendations	How often the molecular tumor board's recommendations are accepted	Up to 5 years
Primary	Benefit from PMMTB recommended treatment	Whether patients benefit from PMMTB recommended treatment	Up to 5 years
Secondary	Correlation of mutations with protein overexpression	Correlate mutations identified in tumor tissue with protein overexpression	Up to 5 years
Secondary	Correlations of mutations with circulating tumor DNA	Correlate mutations identified in tumor tissue with circulating tumor DNA	Up to 5 years
Secondary	Correlations of mutations with spheroid culture investigations	Correlate mutations identified in tumor tissue with spheroid culture investigations	Up to 5 years

External Links

•   UW Carbone Cancer Center Home Page